Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain

BMC Medical Genomics

Wendy A Henderson²  Margaret M Heitkemper¹  Xiao Min Wang²  Ryan Longchamps²  Jessica Gill²  Angela C Martino²  Rebecca S Berger²  Nicolaas H Fourie²  Nat A Rasmussen²  Swarnalatha Y Reddy² 

[1] University of Washington, School of Nursing, Seattle, WA, USA;Division of Intramural Research, National Institute of Nursing of Research, National Institutes of Health, Department of Health and Human Resources, 10 Center Drive, Building 10, 2-1341, Bethesda 20892, MD, USA

关键词: Chronic abdominal pain;    BDNF;    Gene expression;    Sleep;   

Others  :  1090285
DOI  :  10.1186/s12920-014-0061-1

 received in 2013-08-08, accepted in 2014-10-09,  发布年份 2014

【 摘 要 】

Background

Sleep quality and genetics may contribute to the etiology of gastrointestinal (GI) symptoms. Individuals with impaired sleep often have a number of associated symptoms including chronic abdominal pain (CAP). The current study examined the interactions of brain-derived neurotrophic factor (BDNF) genotype with sleep quality in persons with CAP and healthy controls. In addition, associations among sleep quality, BDNF genotype, and gene expression were explored in the participants.

Methods

Data were collected on 59 participants (46% male, 61% White, 26.9 ± 6.6 years; CAP (n=19) and healthy controls (n=40)). Participants with CAP reported poorer sleep quality compared to healthy controls. BDNF genotype, categorized as Val/Val homozygotes versus the Met carriers.

Results

Microarray analysis found twenty-four differentially expressed genes by a two-fold magnitude in participants with poor sleep quality compared to good sleep quality, and seven differentially expressed genes comparing CAP to healthy control. Three specific genes in the pain group overlap with sleep quality, including insulin-like growth factor 1 (IGF1), spermatogenesis associated serine-rich 2-like (SPATS2L), and immunoglobulin heavy constant gamma 1 or mu (IGHG1/// IGHM). BDNF was shown to have an interaction effect with GI and sleep symptoms.

Conclusions

Participants with CAP reported poor sleep quality compared to healthy controls. The role of the BDNF Met allele on differential gene expression was not distinct as main factor, but impacted interactions with sleep quality and CAP. Down-regulation of IGF1, SPATS2L, and IGHG1 expression may be related to the etiology of poor sleep quality and CAP.

Trial registration

Clinicaltrial.gov # NCT00824941 webcite

【 授权许可】

   
2014 Reddy et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, Guthrie E, Read N, Thompson D: Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001, 134(9 Pt 2):860-868.
• [2]Russo MW, Gaynes BN, Drossman DA: A national survey of practice patterns of gastroenterologists with comparison to the past two decades. J Clin Gastroenterol 1999, 29(4):339-343.
• [3]Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130(5):1377-1390.
• [4]Melotti RM, Samolsky-Dekel BG, Ricchi E, Chiari P, Di Giacinto I, Carosi F, Di Nino G: Pain prevalence and predictors among inpatients in a major Italian teaching hospital. A baseline survey towards a pain free hospital. Eur J Pain (London, England) 2005, 9(5):485-495.
• [5]Vallano A, Malouf J, Payrulet P, Banos JE: Prevalence of pain in adults admitted to Catalonian hospitals: a cross-sectional study. Eur J Pain (London, England) 2006, 10(8):721-731.
• [6]Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl 2):1143-1147.
• [7]Ashburn TT, Gupta MS: The IBS market. Nat Rev Drug Discov 2006, 5(2):99-100.
• [8]Spinelli A: Irritable bowel syndrome. Clin Drug Investig 2007, 27(1):15-33.
• [9]Buxton OM, Marcelli E: Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. Social Sci Med (1982) 2010, 71(5):1027-1036.
• [10]Cirelli C, Tononi G: Is sleep essential? PLoS Biol 2008, 6(8 - e216):1605-1611.
• [11]Nicholl BI, Halder SL, Macfarlane GJ, Thompson DG, O’Brien S, Musleh M, McBeth J: Psychosocial risk markers for new onset irritable bowel syndrome–results of a large prospective population-based study. Pain 2008, 137(1):147-155.
• [12]Maneerattanaporn M, Chey WD: Sleep disorders and gastrointestinal symptoms: chicken, egg or vicious cycle? Neurogastroenterol Motil 2009, 21(2):97-99.
• [13]Heitkemper M, Charman AB, Shaver J, Lentz MJ, Jarrett ME: Self-report and polysomnographic measures of sleep in women with irritable bowel syndrome. Nurs Res 1998, 47(5):270-277.
• [14]Chen CL, Liu TT, Yi CH, Orr WC: Evidence for altered anorectal function in irritable bowel syndrome patients with sleep disturbance. Digestion 2011, 84(3):247-251.
• [15]Roehrs TA: Does effective management of sleep disorders improve pain symptoms? Drugs 2009, 69(2 Suppl):5-11.
• [16]Bachmann V, Klein C, Bodenmann S, Schafer N, Berger W, Brugger P, Landolt HP: The BDNF Val66Met polymorphism modulates sleep intensity: EEG frequency- and state-specificity. Sleep 2012, 35(3):335-344.
• [17]Yu YB, Zuo XL, Zhao QJ, Chen FX, Yang J, Dong YY, Wang P, Li YQ: Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012, 61(5):685-694.
• [18]Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H: Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009, 29(8):834-842.
• [19]Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28(2):193-213.
• [20]Alexopoulos GS, Glatt CE, Hoptman MJ, Kanellopoulos D, Murphy CF, Kelly RE Jr, Morimoto SS, Lim KO, Gunning FM: BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord 2010, 125(1–3):262-268.
• [21]Bath KG, Lee FS: Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006, 6(1):79-85.
• [22]Teo JT, Bentley G, Lawrence P, Soltesz F, Miller S, Wille D, McHugh S, Dodds C, Lu B, Croft RJ, Bullmore ET, Nathan PJ: Late cortical plasticity in motor and auditory cortex: role of met-allele in BDNF Val66Met polymorphism. Int J Neuropsychopharmacol 2014, 17(5):705-713.
• [23]Bellini M, Gemignani A, Gambaccini D, Toti S, Menicucci D, Stasi C, Costa F, Mumolo MG, Ricchiuti A, Bedini R, Bardoli ND, Marchi S: Evaluation of latent links between irritable bowel syndrome and sleep quality. World J Gastroenterol 2011, 17(46):5089-5096.
• [24]Elsenbruch S, Harnish MJ, Orr WC: Subjective and objective sleep quality in irritable bowel syndrome. Am J Gastroenterol 1999, 94(9):2447-2452.
• [25]Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999, 22(3):231-238.
• [26]Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS: Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006, 1118(1):176-182.
• [27]Shimizu E, Hashimoto K, Iyo M: Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: the possibility to explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet 2004, 126B(1):122-123.
• [28]Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ: Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003, 123B(1):19-22.
• [29]Nunez A, Rodrigo-Angulo ML, Andres ID, Garzon M: Hypocretin/Orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis. Curr Neuropharmacology 2009, 7(1):50-59.
• [30]Danielsen JM, Sylvestersen KB, Bekker-Jensen S, Szklarczyk D, Poulsen JW, Horn H, Jensen LJ, Mailand N, Nielsen ML: Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. Mol Cell Proteomics 2011, 10(3):M110 003590.
• [31]Consortium WTCC: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447(7145):661-678.
• [32]Polyak MJ, Li H, Shariat N, Deans JP: CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008, 283(27):18545-18552.
• [33]Barcelo A, Barbe F, de la Pena M, Martinez P, Soriano JB, Pierola J, Agusti AG: Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008, 63(11):946-950.
• [34]Makino S, Fujiwara M, Handa H, Fujie T, Aoki Y, Hashimoto K, Terada Y, Sugimoto T: Plasma dehydroepiandrosterone sulphate and insulin-like growth factor I levels in obstructive sleep apnoea syndrome. Clin Endocrinol (Oxf) 2012, 76(4):593-601.
• [35]Lanfranco F, Motta G, Minetto MA, Ghigo E, Maccario M: Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: an update. J Endocrinol Invest 2010, 33(3):192-196.
• [36]Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV: Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001, 11(6):364-367.
• [37]Street ME, de’Angelis G, Camacho-Hubner C, Giovannelli G, Ziveri MA, Bacchini PL, Bernasconi S, Sansebastiano G, Savage MO: Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease. Hormone Res 2004, 61(4):159-164.
• [38]Bortvedt SF, Lund PK: Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors. Curr Opin Gastroenterol 2012, 28(2):89-98.
• [39]Theiss AL, Fruchtman S, Lund PK: Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis 2004, 10(6):871-880.
• [40]Fordjour L, D’Souza A, Cai C, Ahmad A, Valencia G, Kumar D, Aranda JV, Beharry KD: Comparative effects of probiotics, prebiotics, and synbiotics on growth factors in the large bowel in a rat model of formula-induced bowel inflammation. J Pediatr Gastroenterol Nutr 2010, 51(4):507-513.
• [41]Eivindson M, Gronbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF: The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn’s disease. Scand J Gastroenterol 2007, 42(4):464-470.
• [42]Savage MO: Growth-promoting hormone therapy in inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010, 51(Suppl 3):S135-S136.